Pembrolizumab + BCG

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

High-risk Non-muscle Invasive Bladder Cancer

Conditions

High-risk Non-muscle Invasive Bladder Cancer

Trial Timeline

Dec 24, 2018 → Nov 20, 2034

NCT ID

NCT03711032

About Pembrolizumab + BCG

Pembrolizumab + BCG is a phase 3 stage product being developed by Merck for High-risk Non-muscle Invasive Bladder Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03711032. Target conditions include High-risk Non-muscle Invasive Bladder Cancer.

What happened to similar drugs?

0 of 4 similar drugs in High-risk Non-muscle Invasive Bladder Cancer were approved

Approved (0) Terminated (1) Active (3)

🔄SHR3680 + PlaceboJiangsu Hengrui MedicinePhase 3

🔄DAPA/MET XR + DAPA + MET XRAstraZenecaPhase 3

🔄Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Etoposide + Rituximab + Doxorubicin + Vincristine + PrednisoneGilead SciencesPhase 3

❌EsmololBaxterPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03711032	Phase 3	Active	Dec 24, 2018	Nov 20, 2034	High-risk Non-muscle Invasive Bladder Cancer

Competing Products

13 competing products in High-risk Non-muscle Invasive Bladder Cancer

See all competitors

Product	Company	Stage	Hype Score
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II	GT Biopharma	Phase 1/2	14
SHR3680 + Placebo	Jiangsu Hengrui Medicine	Phase 3	47
DAPA/MET XR + DAPA + MET XR	AstraZeneca	Phase 3	40
Blinatumomab + Investigator's Choice Chemotherapy + Dexamethasone	Amgen	Phase 2	35
Blinatumomab	Amgen	Phase 2	27
Axicabtagene Ciloleucel + Cyclophosphamide + Fludarabine + Etoposide + Rituximab + Doxorubicin + Vincristine + Prednisone	Gilead Sciences	Phase 3	47
Darolutamide + ADT	Bayer	Phase 2	39
Esmolol	Baxter	Phase 3	29
N-803 (IL-15 Superagonist) + ETBX-071 (PSA-based Oncolytic Virus) + M-CENK (Activated NK Cells)	ImmunityBio	Phase 2	39
N-803 + ETBX-071 + M-CENK	ImmunityBio	Phase 2	39
Cretostimogene Grenadenorepvec	CG Oncology	Phase 2	39
RP2 Injection	Replimune	Phase 2	36
R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7	PDS Biotechnology	Phase 1	19